ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO722

The Influence of Duration of Peritoneal Dialysis on the Proteomic and Metabolomic Profiles of Plasma and Peritoneal Fluid

Session Information

  • Peritoneal Dialysis - II
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 608 Peritoneal Dialysis

Authors

  • Luczak, Magdalena, Polish Academy of Sciences, Pozna?, Poland
  • Formanowicz, Dorota, Poznan University of Medical Sciences, Pozna?, Poland
  • Tracz, Joanna, Polish Academy of Sciences, Pozna?, Poland
  • Pawliczak, Elzbieta, Poznan University of Medical Sciences, Pozna?, Poland
  • Schwermer, Krzysztof, Poznan University of Medical Sciences, Pozna?, Poland
  • Wanic-Kossowska, Maria, Poznan University of Medical Sciences, Pozna?, Poland
Background

Long-term peritoneal dialysis (PD) is associated with changes of the peritoneal membrane. The major goal of this study was investigation of the effect of PD duration on metabolomic and proteomic profiles of peritoneal fluid (PF) and plasma in order to identify molecular changes occurring through long PD duration.

Methods

Plasma and PF samples were obtained from 35 diabetes and non-diabetes PD recipients in four time-points: at the time of initiation of PD (T1) and after 3 (T2), 6 (T3) and 12 months (T4) of PD. Collected 280 samples were analyzed using LC-ESI-MS/MS and GC-EI-MS/MS. Qualitative and quantitative differences in the accumulation of the individual proteins and metabolites were determined.

Results

One hundred forty-two ANOVA significant differential molecules were identified in plasma and PF samples when time T1 and T4 were compared. For example increased accumulation of CD59 glycoprotein, proliferation-inducing protein 33, insulin-like growth factor-binding protein 4 and 6 were revealed in PF of T4 diabetic samples compared to their T1. The same proteins did not differed T1 and T4 PF samples if derived from non-diabetes. One of the most interesting result concerned monocyte antigen CD14 and lipopolysaccharide-binding protein. Both proteins differentiated T1 and T4 plasma and PF samples obtained from non-diabetes and diabetes but in completely different way. The abundance of CD14 antigen was increased in PF of T4 non-diabetic patients (fold change 3.5; p = 0.004) compared with T1 and in plasma of diabetes (fold change 2.4; p = 0.02). In turn, accumulation of CD14 was 3.4 times lower in PF of T4 diabetic (p = 0.02) and 3.2 times lower (p = 0.005) in T4 plasma of non-diabetes.

Conclusion

Obtained data indicate that PD duration is strongly associated with alterations in proteomic and metabolomic profiles of plasma and PF. Patients starting PDs differed considerably in abundance of many molecules compared to the same patients after 1 year of PD. However large differences in accumulation of proteins between diabetes and non-diabetes may suggest that in these patients molecular mechanisms related to these variations are differ. Especially interesting are differences concerning CD14, a key pattern recognition receptor of the innate immune system.